Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Short term Debt (2017 - 2025)

Avanos Medical's Short term Debt history spans 6 years, with the latest figure at $9.4 million for Q3 2024.

  • For Q3 2024, Short term Debt rose 51.61% year-over-year to $9.4 million; the TTM value through Sep 2024 reached $9.4 million, up 51.61%, while the annual FY2023 figure was $8.6 million, 38.71% up from the prior year.
  • Short term Debt for Q3 2024 was $9.4 million at Avanos Medical, down from $10.2 million in the prior quarter.
  • Across five years, Short term Debt topped out at $10.2 million in Q2 2024 and bottomed at $4.7 million in Q2 2022.
  • The 3-year median for Short term Debt is $6.2 million (2022), against an average of $7.3 million.
  • The largest annual shift saw Short term Debt changed 0.0% in 2023 before it soared 64.52% in 2024.
  • A 3-year view of Short term Debt shows it stood at $6.2 million in 2022, then surged by 38.71% to $8.6 million in 2023, then rose by 9.3% to $9.4 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Short term Debt are $9.4 million (Q3 2024), $10.2 million (Q2 2024), and $9.4 million (Q1 2024).